

basilea

Welcome



Program

Welcome

Basilea's story – Our vision and mission

Strategic alignment – Our business model for financial growth

Innovative compounds in the anti-infectives area – Our exciting portfolio

Coffee break & Networking





Program

Treating infectious diseases

Progress, current limitations and future needs

- Prof. Oliver A. Cornely – Invasive fungal infections
- Prof. Thomas L. Holland – *Staphylococcus aureus* bacteremia

Round table and Q&A

Key takeaways & wrap-up

Networking & Apéro



A portrait of David Veitch, a middle-aged man with short grey hair, wearing a dark blue suit jacket over a white button-down shirt. He is smiling slightly and looking towards the camera. The background is a blurred indoor setting with warm lighting.

basilea

David Veitch

Chief Executive Officer



basilea

basilea

basilea

BSLN



What we do

Serious bacterial & fungal infections



Successful track record of sales performance



**\$ 500 million – \$ 1 billion
revenues in the market**



Creating a broad portfolio

Products / Product candidates / Indication

Cresamba® (savuconazole)

Invasive aspergillitis and mucormycosis (US, EU, China and several other countries)
Aspergillitis (including invasive aspergillitis and chronic pulmonary aspergillitis), mucormycosis and cryptococcosis (Japan)

Fosmanogepix

Cardiacitis / invasive candidiasis (including Candida auris)
Invasive mold infections including invasive aspergillitis, fusariosis, Scedosporium and Lomentospora infections, mucormycosis and other rare mold infections

BAL2062²

Invasive aspergillitis

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)
Staphylococcus aureus bacteremia (SABP), acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) (US)

Tonabacase³

Severe staphylococcal infections

LpTA inhibitors⁴

Severe Enterobacteriaceae infections

Internal research

Focus for in-licensing and acquisitions

¹ The pipeline table and approval table may only be used to identify
² Approved in 2023
³ Phase 1 program (NCT03824444) and Phase 2 program (NCT03824444) are ongoing in the US, Europe and Japan
⁴ Phase 1 program (NCT03824444) and Phase 2 program (NCT03824444) are ongoing in the US, Europe and Japan

Antibacterials

Zevtera

Tonabacase

LptA inhibitor

Antifungals

Cresemba

Fosmanogepix

BAL2062

basilea

Our capabilities



basilea

Partnerships



Industry

Non-profit organizations



CARB-X

A woman with dark hair, wearing a light-colored patterned sweater, is smiling and looking towards a man. The man is wearing glasses and a light blue shirt, looking back at her. They are in a meeting room with a white table in the foreground. A third person, seen from the back, is wearing a white shirt and is looking towards the woman and man. The background shows a window with blinds.

Unique & successful business model

Clear vision and mission





**Leader in
anti-infectives**

Making a difference to patients



7.7 million people

die every year due to bacterial infections

6.5 million people

are affected by invasive fungal infections every year
and 3.8 million people die, with 2.5 million deaths directly attributable to that fungal disease

Global systemic antifungals market 2023:

4.4 billion
USD

Global systemic hospital antibiotics market 2023:

17.8 billion
USD

Challenges



basilea

Creating anti-infective opportunities



How?

basilea

**Our recipe
for success**

basilea

6

elements for success

1.

**Identify opportunities
in anti-infectives**

Our recipe for success

How we create
anti-infective opportunities

Identify opportunities in anti-infectives

- Focus on areas with meaningful market opportunity today
- Focus on high priority diseases/pathogens

2.

**Extend portfolio with
external assets**

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens

Extend portfolio with external assets

- Affordable assets to in-license and acquire

3.

**Define right development stage
to create value**

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire

Define right development stage to create value

4.

**Have sufficient cash
to finance R&D**

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
Have sufficient cash to finance R&D

5.

**Gain access to non-dilutive
funding**

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
 - Gain access to non-dilutive funding

6.

**Reduce the failure potential and
maximize the success potential**

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
 - ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire
 - ✓ **Define right development stage to create value**
 - ✓ **Have sufficient cash to finance R&D**
 - ✓ **Gain access to non-dilutive funding**
- Reduce the failure potential and maximize the success potential**
- Commercialization by established partners
 - Select and prioritize assets through the scientific and commercial lens
 - Accept the development risk for the commercial gain

Great investment opportunity



basilea

basilea


A portrait of Adesh Kaul, a man with short dark hair, wearing a blue blazer over a light blue button-down shirt and a brown belt. He is standing in a well-lit, modern interior space with a blurred background.

basilea

Adesh Kaul

Chief Financial Officer

Our business model


 **CRESEMBA[®]** **100 mg**
hard capsules


Isavuconazole

Oral use.

Each hard capsule contains 100 mg isavuconazole
(as 186.3 mg isavuconazonium sulfate)

14 hard capsules





EU/1/15/1036/002



 **Zevtera[®]** **500 mg**
powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).
*Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.*

For intravenous use after reconstitution and dilution.
Read the package leaflet before use.

10 vials

Key success factors

basilea

Cover the entire pharmaceutical value chain

Lean & cost-effective


A photograph of two business professionals shaking hands in a modern office setting. The person on the left is wearing a light-colored blazer, and the person on the right is wearing a blue blazer over a blue shirt. The background is a blurred office environment with a wooden desk and a white wall.

Leveraging partnerships



**Making long-term
decisions out of
a position of
financial strength**

Our business model



Our business model



Our business model

Preclinical

Phase 1

Phase 2

Phase 3

Market

1.

Acquisition/
in-licensing
of innovative
anti-infective
drugs

2.

**Adding value
through R&D**

3.

Manufacturing and
commercialization
through partners

Our business model



Our business model



1.

Acquisition/ in-licensing of innovative anti-infective drugs

- In-licensing and acquisition of the most promising assets (research and early clinical development stages)

Our business model

Preclinical

Phase 1

Phase 2

Phase 3

Market

1.

Acquisition/
in-licensing
of innovative
anti-infective
drugs

2.

Adding value
through R&D

3.

Manufacturing and
commercialization
through partners

2.

Adding value through R&D


- Focusing R&D investments on innovative assets with a clearly defined hypothesis on clinical differentiation and commercial positioning



CARB-X

- Offsetting R&D expenses through **accessing non-dilutive push-incentives**

Our business model



3.

Manufacturing and commercialization through partners

- Manufacturing through contract manufacturing organizations (CMOs)
- Commercialization through partnerships with global, regional and local specialized pharmaceutical partners

License partners



AsahiKASEI



Distribution partners



hikma.




LANCET




Financial participation in in-market product sales



Basilea: 30-40% of in-market product sales over the lifetime of a product



Product in-market sales



0% 20% 40% 60% 80% 100%

Basilea revenue participation




Basilea gross margin

Internal program



Early acquisition



Late acquisition



Basilea expected gross margin

Successful products

 **CRESEMBA[®]** **100 mg**
hard capsules

Isavuconazole

Oral use.

Each hard capsule contains 100 mg isavuconazole
(as 186.3 mg isavuconazonium sulfate)

14 hard capsules





EU/1/15/1036/002



 **Zevtera[®]** 500 mg
powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).

*Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.*


For intravenous use after reconstitution and dilution.
Read the package leaflet before use.

10 vials

Cresemba® double-digit growth

USD 473 million
in-market sales in
the 12 months to
December 2023

Cresemba® in-market sales in USD million



- Other
- UK
- China
- Germany
- Spain
- Italy
- France
- US


MAT: Moving annual total;
Source: IQVIA Analytics Link, December 2023



Global sales of best-in-class antifungals* (MAT Q4 2023)

Cresemba® has significant growth potential

Recently launched in Japan and China,
representing 25% of global potential



MAT: Moving annual total; Source: IQVIA Analytics Link, December 2023

* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin, rezafungin

basilea

basilea

 **Zevtera**[®] 500 mg

powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).

*Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.*


For intravenous use after reconstitution and dilution.
Read the package leaflet before use.

10 vials

Daptomycin sales by region (2015, before LOE)

The hospital anti-MRSA antibiotic market

A USD 2.4 billion market* with the US being the most important region



MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest Of World; MAT: Moving annual total; Source: IQVIA Analytics Link, December 2023

* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, ceftobiprole, oritavancin, and tedizolid (daptomycin and tigecycline are partial sales in the US in IQVIA data)


United States Commercial partner

Process completion around mid-year 2024


This commercial success
gives us the financial strength for

**creating long-term
value and growth**

Cash flows from operating activities (in CHF million)



Debt reduction (in CHF million)



Strong 2024 guidance

20% increase in Cresemba and Zevtera related revenue and more than doubling of net profit

In CHF million	FY 2022	FY 2023 guidance	FY 2023	FY 2024 guidance
Cresemba and Zevtera related revenue	122.3	147 – 150	150.3	~180
of which royalty income	65.0	~76	78.9	~89
Total revenue	147.8	154 – 157	157.6	~183
Cost of products sold	24.6	~27	26.8	~33
Operating expenses	104.6	~115	111.6	~120
Operating profit	18.5	11 – 15	19.2	~30
Net profit	12.1	2 – 6	10.5	~25

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
- ✓ **Gain access to non-dilutive funding**
- ✓ **Reduce the failure potential and maximize the success potential**
 - Commercialization by established partners
 - Select and prioritize assets through the scientific and commercial lens
 - Accept the development risk for the commercial gain



basilea

basilea

A portrait of Marc Engelhardt, a middle-aged man with short grey hair and glasses, wearing a dark blue suit jacket over a light blue button-down shirt. He is standing in a brightly lit hallway with a blurred background. The image is positioned on the left side of the page.

basilea

Marc Engelhardt

Chief Medical Officer

Successful products

 **CRESEMBA®** **100 mg**
hard capsules

Isavuconazole

Oral use.
Each hard capsule contains 100 mg isavuconazole
(as 186.3 mg isavuconazonium sulfate)

14 hard capsules





EU/1/15/1036/002



 **Zevtera®** **500 mg**
powder for concentrate for solution for infusion.
Ceftobiprole (as ceftobiprole medocaril sodium).

*Each vial contains 500 mg of ceftobiprole,
equivalent to 666.6 mg of ceftobiprole medocaril sodium.*

For intravenous use after reconstitution and dilution.
Read the package leaflet before use.

10 vials

Future



Portfolio USPs

- Serious infections (in hospital)
- Medical need
- Innovative and differentiated for successful commercialization

Our portfolio

Products / Product candidates / Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Antifungals

Cresemba® (isavuconazole)

Invasive aspergillosis and mucormycosis (US, EU, China and several other countries)¹

Aspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)



Fosmanogepix

Candidemia / invasive candidiasis (including *Candida auris*)

invasive mold Infections including invasive aspergillosis, fusariosis, *Scedosporium* and *Lomentospora* infections, mucormycosis and other rare mold infections)



BAL2062²

Invasive aspergillosis



Antibiotics

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)

Staphylococcus aureus bacteremia (SAB)³, acute bacterial skin and skin structure infections (ABSSSI)³ and community-acquired bacterial pneumonia (CABP) (US)



Tonabacase⁴

Severe staphylococcal infections



LptA inhibitor⁵

Severe Enterobacteriaceae infections



Internal research



Focus for in-licensing and acquisitions



¹ The registration status and approved indications may vary from country to country.

² Formerly GR-2397

³ Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).

⁴ Exclusive option to in-license upon completion of preclinical profiling

⁵ CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

High medical need in invasive fungal infections

The new assets in our drug pipeline

Products / Product candidates / Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Antifungals

Cresemba® (isavuconazole)

Invasive aspergillosis and mucormycosis (US, EU, China and several other countries)¹

Aspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)



Fosmanogepix

Candidemia / invasive candidiasis (including *Candida auris*)

invasive mold Infections including invasive aspergillosis, fusariosis, *Scedosporium* and *Lomentospora* infections, mucormycosis and other rare mold infections)



BAL2062²

Invasive aspergillosis



Antibiotics

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)

Staphylococcus aureus bacteremia (SAB)³, acute bacterial skin and skin structure infections (ABSSSI)³ and community-acquired bacterial pneumonia (CABP) (US)



Tonabacase⁴

Severe staphylococcal infections



LptA inhibitor⁵

Severe Enterobacteriaceae infections



Internal research



Focus for in-licensing and acquisitions



¹ The registration status and approved indications may vary from country to country.

² Formerly GR-2397

³ Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).

⁴ Exclusive option to in-license upon completion of preclinical profiling

⁵ CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

A 3D digital illustration of a plant with several brown, woody branches. The branches are covered with numerous spherical, pinkish-purple fruits that have a textured, almost crystalline surface. The background is a soft, out-of-focus gradient of light blue and green, suggesting a natural outdoor setting. The overall aesthetic is clean and modern, typical of a corporate or scientific presentation.


basilea

Fosmanogepix

An attractive asset with high potential


Estimated annual crude mortality of severe fungal disease, worldwide (thousands)

0 250 500 750 1000 1250 1500 1750 2000



Fosmanogepix

Fosmanogepix:
an attractive
asset with
high potential



Fosmanogepix

Innovative, new class of antifungal

- Broad spectrum antifungal activity against yeasts, molds and dimorphic fungi
- May become the treatment of choice for a wide range of difficult to treat fungal infections
- Planned global phase 3 program includes two studies in yeast and in mold infections

basilea

Fosmanogepix saving lives

in fungal meningitis outbreaks

Products / Product candidates / Indication

Preclinical Phase 1 Phase 2 Phase 3 Market

Antifungals

Cresemba® (isavuconazole)

Invasive aspergillosis and mucormycosis (US, EU, China and several other countries)¹

Aspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)



Fosmanogepix

Candidemia / invasive candidiasis (including *Candida auris*)

invasive mold Infections including invasive aspergillosis, fusariosis, *Scedosporium* and *Lomentospora* infections, mucormycosis and other rare mold infections)



BAL2062²

Invasive aspergillosis



Antibiotics

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)

Staphylococcus aureus bacteremia (SAB)³, acute bacterial skin and skin structure infections (ABSSSI)³ and community-acquired bacterial pneumonia (CABP) (US)



Tonabacase⁴

Severe staphylococcal infections



LptA inhibitor⁵

Severe Enterobacteriaceae infections



Internal research



Focus for in-licensing and acquisitions




¹ The registration status and approved indications may vary from country to country.
² Formerly GR-2397
³ Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
⁴ Exclusive option to in-license upon completion of preclinical profiling
⁵ CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

basilea

BAL2062

The fastest acting drug in Aspergillosis

BAL2062



BAL2062

First-in-class, fast-acting antifungal

- First-in-class antifungal with novel mechanism of action for intravenous administration
- Rapid fungicidal activity in vitro against *Aspergillus* spp.
- Lack of cross resistance with marketed antifungal agents
- Low propensity for drug-drug interactions
- Potential to be superior to other antifungals in the treatment of invasive aspergillosis
- Preclinical profiling to inform clinical development program aimed for demonstrating superiority



High medical need in bacterial infections

Products / Product candidates / Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

Antifungals

Cresemba® (isavuconazole)

Invasive aspergillosis and mucormycosis (US, EU, China and several other countries)¹

Aspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)



Fosmanogepix

Candidemia / invasive candidiasis (including *Candida auris*)

invasive mold Infections including invasive aspergillosis, fusariosis, *Scedosporium* and *Lomentospora* infections, mucormycosis and other rare mold infections)



BAL2062²

Invasive aspergillosis



Antibiotics

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)

Staphylococcus aureus bacteremia (SAB)³, acute bacterial skin and skin structure infections (ABSSSI)³ and community-acquired bacterial pneumonia (CABP) (US)



Tonabacase⁴

Severe staphylococcal infections



LptA inhibitor⁵

Severe Enterobacteriaceae infections



Internal research



Focus for in-licensing and acquisitions



¹ The registration status and approved indications may vary from country to country.

² Formerly GR-2397

³ Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).


⁴ Exclusive option to in-license upon completion of preclinical profiling

⁵ CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).


basilea

Tonabacase

Great potential of showing superiority




Tonabacase (endolysin) effects on Gram-positive bacteria



Tonabacase

Innovative new class of antibiotic

- Innovative new class of antibiotic (endolysin), rapidly bactericidal
- Effective against biofilms
- Low risk of resistance development
- Different from exebacase, due to ability of multiple dosing
- Preclinical profiling to inform clinical development program aimed for demonstrating superiority
- Clinical development in serious staphylococcal infections such as endocarditis as add-on to standard of care antibiotics



Products / Product candidates / Indication

Preclinical Phase 1 Phase 2 Phase 3 Market

Antifungals

Cresemba® (isavuconazole)

Invasive aspergillosis and mucormycosis (US, EU, China and several other countries)¹

Aspergillosis (including invasive aspergillosis and chronic pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)



Fosmanogepix

Candidemia / invasive candidiasis (including *Candida auris*)

invasive mold Infections including invasive aspergillosis, fusariosis, *Scedosporium* and *Lomentospora* infections, mucormycosis and other rare mold infections)



BAL2062²

Invasive aspergillosis



Antibiotics

Zevtera® (ceftobiprole)

Hospital- and community-acquired bacterial pneumonia (HABP, CABP) (major European and several other countries)

Staphylococcus aureus bacteremia (SAB)³, acute bacterial skin and skin structure infections (ABSSSI)³ and community-acquired bacterial pneumonia (CABP) (US)



Tonabacase⁴

Severe staphylococcal infections



LptA inhibitor⁵

Severe Enterobacteriaceae infections



Internal research



Focus for in-licensing and acquisitions



¹ The registration status and approved indications may vary from country to country.
² Formerly GR-2397
³ Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).
⁴ Exclusive option to in-license upon completion of preclinical profiling
⁵ CARB-X's funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany's Federal Ministry of Education and Research (BMBF).

basilea

LptA inhibitor



LptA inhibitor

Late preclinical antibacterial compound(s)

- Innovative mode of action
- Targeted spectrum against most frequent Gram-negative bacteria
- Expected to overcome resistance in serious Gram-negative infections
- Non-dilutive funding by CARB-X
- Initiation of clinical development expected in 2026

Overview: new drugs in our pipeline

Antifungals

Fosmanogepix

BAL2062

Antibacterials

Tonabacase

LptA inhibitor

Our recipe for success

How we create
anti-infective opportunities

- ✓ **Identify opportunities in anti-infectives**
 - Focus on areas with meaningful market opportunity today
 - Focus on high priority diseases/pathogens
- ✓ **Extend portfolio with external assets**
 - Affordable assets to in-license and acquire
- ✓ **Define right development stage to create value**
- ✓ **Have sufficient cash to finance R&D**
- ✓ **Gain access to non-dilutive funding**
- ✓ **Reduce the failure potential and maximize the success potential**
 - Commercialization by established partners
 - Select and prioritize assets through the scientific and commercial lens
 - Accept the development risk for the commercial gain



basilea

basilea

The future

2024 Priorities



Maximize Cresemba revenues

A close-up photograph of a person's hand typing on a laptop keyboard. The laptop screen displays a bar chart with several vertical bars in shades of teal and light green, showing an upward trend. The background is blurred, suggesting an office environment.

Zevtera US launch





basilea

Fosmanogepix

Start of phase 3 studies

BAL2062 & tonabacase

2025: Start of phase 2 studies



basilea

Preclinical Phase 1 Phase 2 Phase 3 Market

Antifungals

Products / Product candidates / Indication
Cresemba® (isavuconazole)
Invasive aspergillosis and mucormycosis (EU, China, several other countries)
Aspergillosis (including invasive aspergillosis, pulmonary aspergillosis), mucormycosis and cryptococcosis (Japan)

Fosmanogepix
Candidemia / invasive candidiasis (including candida auris)
Invasive mold infections including invasive aspergillosis, mucormycosis and other rare mold infections

BAL2062²
Invasive aspergillosis

Antibiotics

Zevtera® (ceftobiprole)
Hospital- and community-acquired bacterial pneumonia (US, Canada, Mexico, several other countries)
Staphylococcus aureus bacteremia (SAB), skin and soft tissue infections (US)
Community-acquired bacterial pneumonia (CABP) (major European and several other countries)

Tonabacase⁴
Severe staphylococcal infections

LptA inhibitor⁵
Severe Enterobacteriaceae infections

Internal research
Focus for in-licensing and acquisitions

¹ The registration status and approved indications may vary from country to country.
² Formerly CBI-2062
³ Formerly program funded in part with federal funds from the US Department of Health and Human Services (PHS), Administration for Strategic and Emerging Diseases and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA).
⁴ Evaluation option to in-license upon completion of preclinical program
⁵ CABI's funding for the project is provided in part with federal funds from the Department of Health and Human Services (HHS), Administration for Strategic and Emerging Diseases and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) and by awards from Wellcome (WT204422) and Cancer Research UK (C18615).

Broaden our portfolio

Solid financial basis



basilea

Thank you!

basilea

Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products,

dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.